RxDoctor Payments DataLook up a doctor →

Bryce Hancock, PA

Physician Assistant · Provo, UTNPI 1457309668

Payments from drug & device makers

$17,489in general payments, 2019–2025

Across 636 payments — averaging $27.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$5K
  • Inspire Medical Systems, Inc.$4K
  • Harmony Biosciences LLC$1K
  • AbbVie$972
  • Lilly USA, LLC$768
  • Axsome Therapeutics, Inc.$578
  • plus $5K from 46 others

What the payments were for

  • Speaking & faculty fees$2,58015%
  • Travel & lodging$3,37219%
  • Food & beverage$11,03763%
  • Education$5003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,489 in reported general payments places this provider in the 95th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$95,252
Medicare patients
574
Services billed
1,924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin19$20,677
FarxigaDapagliflozin Propanediol17$15,987
MyrbetriqMirabegron15$6,674
DayvigoLemborexant11$3,617
Modafinil83$3,554
Gabapentin179$2,518
Armodafinil40$1,771
Trazodone Hcl117$1,068
Tramadol Hcl ErTramadol Hcl15$950
Eszopiclone54$947
Quetiapine Fumarate64$917
Celecoxib32$899
Levothyroxine Sodium79$822
Clonazepam133$757
Atorvastatin Calcium36$712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$281$20,67719 claims
AstraZenecaFarxiga$535$15,98717 claims
Astellas Pharma US IncMyrbetriq$240$6,67415 claims
Eisai Inc.Dayvigo$34$3,61711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Provo

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →